Literature DB >> 11243745

Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started?

L P Ormerod1, N Horsfield, R M Green.   

Abstract

OBJECTIVES: National tuberculosis treatment guidelines suggest a regimen of 2RZE/10RE for the treatment of isoniazid resistant organisms. A retrospective clinical study of all patients treated for non-MDR-TB isoniazid-resistant organisms was undertaken.
METHODS: A continuous database of the patients treated between 1978-1999 inclusive was examined to determine the regimens used and the outcome of treatment for such patients.
RESULTS: Thirty-seven patients were identified. Eighteen had regimens of greater than 9 months, 19 had regimens of 9 months or less. No relapses occurred in those cases treated with a regimen of 2RZE/7RE during 12 months' minimum follow-up.
CONCLUSIONS: A regimen of 2RZE/7RE may be possible for the treatment of isoniazid-resistant organisms if given either under close supervision or as a formally supervised regimen. Larger clinical studies or a controlled clinical trial are needed to confirm these initial findings. Copyright 2001 The British Infection Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11243745     DOI: 10.1053/jinf.2000.0773

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  3 in total

1.  Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.

Authors:  M Gegia; T Cohen; I Kalandadze; L Vashakidze; J Furin
Journal:  Int J Tuberc Lung Dis       Date:  2012-04-09       Impact factor: 2.373

2.  Treatment of isoniazid-resistant pulmonary tuberculosis.

Authors:  Yee Hyung Kim; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Seong Yong Lim; Si Young Lim; Won-Jung Koh
Journal:  BMC Infect Dis       Date:  2008-01-23       Impact factor: 3.090

Review 3.  Treatment of Isoniazid-Resistant Pulmonary Tuberculosis.

Authors:  Byung Woo Jhun; Won Jung Koh
Journal:  Tuberc Respir Dis (Seoul)       Date:  2020-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.